✦ LIBER ✦

Bevacizumab, when Added to Paclitaxel/Carboplatin, Prolongs Survival in Previously Untreated Patients with Advanced Non–Small-Cell Lung Cancer: Preliminary Results from the ECOG 4599 Trial

✍ Scribed by Preeta Tyagi; Chandra P. Belani

Book ID: 114411908
Publisher: CIG Media Group, LP.
Year: 2005
Tongue: English
Weight: 447 KB
Volume: 6
Category: Article
ISSN: 1525-7304
DOI: 10.1016/s1525-7304(11)70220-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O-086a Randomized phase II/III trial of

O-086a Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C)with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599

✍ Sandler, A.B.; Gray, R.; Brahmer, J.; Dowlati, A.; Schiller, J.H.; Perry, M.C.; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 151 KB

Bexarotene in Combination with Chemother

Bexarotene in Combination with Chemotherapy Fails to Prolong Survival in Patients with Advanced Non–Small- Cell Lung Cancer: Results from the SPIRIT I and II Trials

✍ Preeta Tyagi; Chandra P. Belani; Vinay K. Jain 📂 Article 📅 2005 🏛 CIG Media Group, LP. 🌐 English ⚖ 457 KB

Biomarker Analyses and Final Overall Sur

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)

✍ Fukuoka, M.; Wu, Y.-L.; Thongprasert, S.; Sunpaweravong, P.; Leong, S.-S.; Sriur 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 241 KB